Home > Back to Publisher > Report Information

Drug-device Combinations: The Global Market

BCC Research
January 1, 2010
263 Pages - SKU: WA2585171

Abstract Table of Contents Related Reports

Countries covered: Global

THIS REPORT:

Analysis of the technologies for five areas of drug-device combination products, including antimicrobial catheters, biologic wound care products, bone graft substitutes and bone cements, drug-eluting stents and photodynamic therapy (PDT)
Analysis of global markets with data for 2008, estimates for 2009, and projections of 5-year compound annual growth rates through 2014
Detailed discussion of the current regulatory environment for drug-device combination products and how this is affecting development and approval of such devices
Further analysis of overall market trends and competitors, and profiles of selected competitors in the category.

CHAPTER ONE: INTRODUCTION: STUDY GOALS AND OBJECTIVES; REASONS FOR DOING THIS STUDY AND ITS IMPORTANCE; INTENDED AUDIENCE; SCOPE AND FORMAT OF REPORT; METHODOLOGY AND INFORMATION SOURCES; ANALYST CREDENTIALS; BCC ONLINE SERVICES; DISCLAIMER
CHAPTER TWO: EXECUTIVE SUMMARY: SCOPE OF THE INDUSTRY; DRUG-DEVICE COMBINATIONS: THE GLOBAL MARKET; TECHNOLOGY AND PATENT ACTIVITY; THE CENTRAL ROLE OF THE FDA
CHAPTER THREE: CURRENT STATUS OF THE DRUG DEVICE COMBINATION INDUSTRY: OVERVIEW; ROLE OF THE FDA; OFFICE OF COMBINATION PROUCTS ORGANIZATIONAL STRUCTURE; HIGHLY ADVANCED TECHNOLOGIES ARE A MARKET CORE; EXAMPLES OF THE MOST PATH-BREAKING PRODUCTS; FDA CLASSIFICATION SCHEME FOR INDIVIDUAL SEGMENTS; THE RELATION BETWEEN NANOTECHNOLOGY AND COMBINATION PRODUCTS; FDA TRENDS IN REVIEWING COMBINATION PRODUCTS
CHAPTER FOUR: REGULATORY PROCESS AND ISSUES: OVERVIEW; SCOPE OF FDA ACTION; TREATMENT OF DEVICES; CLASS I DEVICES; CLASS II DEVICES; CLASS III DEVICES; CURRENT STATUS OF FDA AND NANOTECHNOLOGY INITIATIVES; FDA NANOTECH PRODUCT APPROVALS; OTHER RELEVANT HEALTH OR REGULATORY AGENCIES; TYPICAL REGULATORY MILESTONES IN COMBINATION PRODUCT APPROVALS; CLINICAL TRIALS
CHAPTER FIVE: NANOTECH COMBINATION PRODUCTS: OVERVIEW; NATIONAL NANOTECHNOLOGY INITIATIVE (NNI); NANOTECH REGULATORY ENVIRONMENT; COMBINATION NANOTECHNOLOGY PRODUCT RESEARCH; NANODIAMOND DRUG DEVICES FOR CANCER TREATMENT; NANOTECHNOLOGY-MAGNETISM COMBINATION IN TINY IMPLANTABLE DEVICE FOR DRUG DELIVERY; IMPLANTS USING CONDUCTING POLYMER NANOTUBES; CALCIUM PHOSPHATE NANOPARTICLES FOR DRUG DELIVERY; NANO-SCALE DELIVERY OPTIMIZES CHEMOTHERAPY REGIMES; DRUG INFUSED NANOPARTICLES; ENCAPSULATION OF DRUG TREATMENTS IN NANOPARTICLES; SILICON NANOWIRES FOR DRUG DELIVERY; MINUTE ANTIBACTERIAL PARTICLES DESTROY DRUGRESISTANT GERMS; BIODEGRADABLE CATIONIC CORE-SHELL NANOPARTICLES FOR CO-DELIVERY OF DRUGS AND GENES; STIMULI-SENSITIVE CORE-SHELL NANOPARTICLES FOR CANCER THERAPY; POLYMER-BASED NON-VIRAL GENE CARRIERS; POTENTIAL HEALTH EFFECTS: IMPACT ON NANO INDUSTRY
CHAPTER SIX: DRUG-ELUTING CORONARY STENTS: OVERVIEW; DEFINITION AND SIZE OF TARGET MARKET; STENT MARKET REINFORCED BY CURRENT RESEARCH FINDINGS; PRINCIPAL DRUG-ELUTED STENT PRODUCERS; STENT DESIGN; PRODUCT LINES; MECHANISM OF ACTION; DEVELOPMENT OF THE INDUSTRY; FDA REGULATORY ROLE WITH REGARD TO STENTS; STENT PRODUCT INNOVATIONS AND R&D: BIOABSORBABLE STENTS; BIODEGRADABLE COATINGS; HYDROXYAPATITE COATINGS; MARKETS FOR STENT RELATED TECHNOLOGIES; LIPISCAN CORONARY IMAGING SYSTEM
CHAPTER SEVEN: PHOTODYNAMIC THERAPY: OVERVIEW; TREATMENT LIMITATIONS; TECHNOLOGY HISTORY; RECENT DEVELOPMENTS; SECOND GENERATION PDT SENSITIZERS; PDT MARKETS FOR CANCER; PDT MARKETS FOR MACULAR DEGENERATION; PDT MARKETS FOR PSORIASIS; TYPES OF UVB THERAPY FOR PSORIASIS; PUVA PHOTOCHEMOTHERAPY; TARGETED PHOTOTHERAPY (EXCIMER LASER); OTHER MEDICAL APPLICATIONS; PDT MARKET GROWTH DRIVERS; EXAMPLE PDT PRODUCTS; VISUDYNE (NOVARTIS); LEVULAN; PHOTOFRIN (PORFIMER SODIUM); VISONAC; CEVIRA; LUMACAN; RESEARCH AND DEVELOPMENT; INTERVENTIONAL CARDIOLOGY; DERMATOLOGY; AUTOIMMUNE DISEASES; EQUIPMENT PRODUCERS
CHAPTER EIGHT: ANTIMICROBIALS AND OTHER MEDICAL DEVICE COATINGS: OVERVIEW: REGULATORY TREATMENT; DRIVING FORCE IN DEVELOPMENT OF ANTI-MICROBIALS; MARKET CONTEXT AND PREVALENCE OF INFECTIONS; EXAMPLES OF USE; TRENDS IN FDA APPLICATIONS FOR ANTIMICROBIALS; ANTI-MICROBIAL AND OTHER MEDICAL DEVICE COATINGS; MARKET CATEGORIES FOR MEDICAL DEVICE COATINGS IN COMBINATION PRODUCTS; EXAMPLE PRODUCTS
CHAPTER NINE: ANTIMICROBIAL CATHETERS: MARKET OVERVIEW; APPLICATIONS; MARKET SIZE; CATHETER INNOVATIONS; ANTIMICROBIAL CATHETER CONCEPTS; EXAMPLE PRODUCTS; 5-FLUOROURACIL-COATED CENTRAL VENOUS CATHETER; DRUG - DEVICE COMBINATION CATHETER LOCK/FLUSH; SOLUTIONS; R&D INITIATIVES; DIALYSIS CATHETERS; URINARY CATHETERS; OTHER DELIVERY TECHNIQUES
CHAPTER TEN: DRUG-ELUTING BEADS: OVERVIEW; EXAMPLE OF THERAPY; COMPANY ACTIVITY; BEAD APPLICATIONS IN STROKE; BEAD APPLICATIONS IN ALLERGY AND ASTHMA ATTACKS; RECENT FDA APPROVALS; RECENT OVERSEAS APPROVALS; CLINICAL TRIALS; TABLE 13 CURRENT CLINICAL TRIALS INVOLVING DRUGELUTING BEADS; R&D AND OTHER NOVEL APPLICATIONS OF BEADS; USING FLUORESCENT SILICA BEADS TO DETECT MALIGNANT CERVICAL CELLS; ANTIBODY COATED MAGNETIC BEADS TO COMBAT INFECTION; FUMAGILLIN NANOPARTICLES; CONTROLLED DELIVERY OF TUMOR-KILLER DRUGS; POLYMERIC MICROCAPSULES
CHAPTER ELEVEN: BONE CEMENTS INCLUDING ANTIBIOTIC: OVERVIEW; EARLY HISTORY; APPLICATIONS; MARKET SIZE; COMPOSITION; EXAMPLE PRODUCTS; RELATED PRODUCTS: TYPES OF CERAMICS; ALPHA-BSM; BIOGRAN; BIO-OSS; BONESOURCE; CALCIGEN S; CEMENTS IN DENTAL APPLICATIONS: GLASS IONOMER CEMENTS; OTHER OSTEOCONDUCTIVE BONE GRAFT SUBSTITUTES
CHAPTER TWELVE: BONE GRAFT SUBSTITUTES: OVERALL SIZE OF BONE GRAFT BUSINESS; BONE GRAFT SUBSTITUTES; ALLOGRAFT TISSUE; OTHER OSTEOCONDUCTIVE BONE-GRAFT SUBSTITUTES; HYDROGELS IN BONE GRAFTING; Composition and Method for Self-Assembly and Mineralization of Peptide Amphiphiles; Chondroitinase ABC I Polynucleotides; Transdiscal Administration of Cycline Compounds; Composition and Method for Preparing Biocompatible Surfaces; Spinal Mobility Preservation Apparatus Having an Expandable Membrane; BONE GRAFTS; AUTOGRAFTS; BioSeed Grafts; Allografts; Demineralized Bone Matrix Products; Accell; AlphaGRAFT; Allomatrix; Grafton DBM; DBX; DynaBlast and DynaGraft-D; Graftech; Grafton; Opteform; OrthoBlast II; Osteofil; Solo Cervical Allograft; Xenografts; THE MARKET FOR ALLOGRAFTS; CELL-BASED BONE GRAFT SUBSTITUTES; FACTOR-BASED BONE GRAFT SUBSTITUTES; BONE MORPHOGENIC PROTEINS; InductOs; INFUSE Bone Graft; OP-1 Implant; CERAMIC-BASED BONE GRAFT SUBSTITUTES; TYPES OF CERAMICS; Alpha-BSM; BioGran; Bio-Oss; BoneSource; Calcigen S; Collagraft Strip Bone Graft Matrix; Conduit TCP Granules; IsoTis Products; Mimix Bone Substitute Material; Norian SRS; OsteoGraf; Osteoset; Osteostim Resorbable Bone Graft Substitute; PerioGlas; Pro Osteon Implant; Vitoss; POLYMER-BASED BONE GRAFT SUBSTITUTES; Cortoss; Healos; Immix Extenders and Immix CB; THE MARKET FOR BONE GRAFT PRODUCTS; REGENERATIVE MEDICINE PRODUCTS IN DEVELOPMENT FOR BONE APPLICATIONS; BIOLOGIC/SYNTHETIC GRAFTS; CHRYSALIN
CHAPTER THIRTEEN: WOUND CARE PRODUCTS INCLUDING BIOLOGICAL DRESSINGS: WOUND CARE GENERALLY; MARKET SEGMENTS; COLLAGEN; COLLAGEN IN MEDICAL APPLICATIONS; SPECIFIC COLLAGEN PRODUCTS; TenoMendTM Collagen Tendon Wrap; CosmoDerm and CosmoPlast Human-Based Collagen; TISSUE ENGINEERING; SKIN SUBSTITUTES: CELLS AND TISSUES; ARTIFICIAL SKIN; SKIN-LIKE TISSUE DEVELOPED FROM HUMAN EMBRYONIC STEM CELLS; ALGINATES; FIBRIN SEALANT PRODUCTS; HISTORY OF FIBRIN SEALANTS; PRODUCTS; Evicel; Artiss; ReCell; RELATED PRODUCTS: FIRST FDA APPROVED SPINE SEALANT; ENZYMATIC DEBRIDING AGENTS; NANOSTRUCTURED TEMPERATURE-SENSITIVE MEMBRANES FOR WOUND HEALING AND CELL GRAFTING
CHAPTER FOURTEEN: DRUG DEVICE COMBINATION PRODUCTS FOR OCCULAR APPLICATIONS: OVERVIEW; INTRAOCULAR LENS PRODUCTS; LENS MATERIALS; CLEAR LENS EXTRACTION AND REPLACEMENT (CLEAR) SURGERY; VITREOUS SUBSTITUTES; Polymers; Perfluorocarbon Liquids (PFCL); Silicone Oil; Combination Product: PFCL and Silicone Oil; OCULAR DRUG DELIVERY VIA NANOSTRUCTURED DRUG-LOADED CONTACT LENSES; MARKET POTENTIAL
CHAPTER FIFTEEN: IMPLANTABLES AS DRUG DEVICE COMBINATIONS: MINIATURE NEUROSTIMULATORS; BIODEGRADABLE CIRCUITS; STEROID ELUTING PACEMAKER LEADS; MARKET SIZE
CHAPTER SIXTEEN: RELATED DRUG DEVICE COMBINATIONS OF RELEVANCE: OVERVIEW; MARKET SIZE; INJECTABLE BIODEGRADABLE HYDROGELS FOR DRUG DELIVERY AND TISSUE ENGINEERING; RADIATION/DRUG COMBINATIONS; ANTI-BACTERIAL RELEASING DENTAL RESTORATIVE MATERIALS; COMBINATION DENTAL PROPHYLAXIS PASTES AND DRUG COMPONENTS; METERED DOSE INHALERS, SPACERS AND OTHER ACCESSORIES; ANTIMICROBIAL SUTURES; ANTIMICROBIAL VASCULAR GRAFTS; HEAT-ACTIVATED DRUGS; BREATH TEST COMBINATION PRODUCTS; MYOCELL THERAPY BY BIOHEART, INC.; OTHER NEW DRUG DELIVERY CONCEPTS
CHAPTER SEVENTEEN: PATENT ANALYSIS: OVERVIEW; OTHER INTELLECTUAL PROPERTY ISSUES; EXAMPLE DRUG-DEVICE COMBINATION PATENTS: 2008 TO 2009; ELECTROPROCESSED COLLAGEN AND TISSUE ENGINEERING; BIOFUNCTIONAL, ANTIMICROBIAL COATINGS FOR MEDICAL DEVICES; GELATIN DERIVATIVES AND HIGH-MOLECULAR MICELLE COMPRISING THE DERIVATIVES; METHODS AND APPARATUS FOR ACUTE OR CHRONIC DELIVERY OF SUBSTANCES OR APPARATUS TO EXTRAVASCULAR TREATMENT SITES; WOUND COVERING; NANOPARTICLES FOR PROTEIN DRUG DELIVERY; PROCESS FOR PROVIDING ANTIMICROBIAL SURFACES; GROWTH FACTOR MODIFIED PROTEIN MATRICES FOR TISSUE ENGINEERING; METHOD OF COATING IMPLANTABLE MEDICAL DEVICES; ANTIMICROBIAL COATING FOR EROSIVE ENVIRONMENTS; METHOD AND COMPOSITION FOR PRODUCING CATHETERS WITH ANTIBACTERIAL PROPERTY; IMPLANTABLE MEDICAL DEVICE WITH ANTI-INFECTION AGENT; MINIATURE DRUG DELIVERY PUMP WITH A PIEZOELECTRIC DRIVE SYSTEM; IONTOPHORESIS DEVICE; APPARATUS FOR COATING MEDICAL DEVICES; COATINGS FOR DRUG DELIVERY DEVICES; THIN-FILM DRUG DELIVERY ARTICLE AND METHOD OF USE; IMPLANTABLE, TISSUE CONFORMING DRUG DELIVERY DEVICE; IMPLANTABLE DEVICE WITH RESERVOIRS FOR INCREASED DRUG LOADING; STENT ASSEMBLY FOR THE TREATMENT OF VULNERABLE PLAQUE; APPLICATION OF A THERAPEUTIC SUBSTANCE TO A TISSUE LOCATION USING AN EXPANDABLE MEDICAL DEVICE; MULTI-STABLE VALVES FOR MEDICAL APPLICATIONS AND METHODS FOR USE THEREOF; METHOD AND APPARATUS FOR DELIVERING COMBINED ELECTRICAL AND DRUG THERAPIES; HEPARIN PRODRUGS AND DRUG DELIVERY STENTS FORMED THEREFROM; NANOPARTICLE ASSEMBLED HOLLOW SPHERES; METHOD OF STENT MOUNTING TO FORM A BALLOON CATHETER HAVING IMPROVED RETENTION OF A DRUG DELIVERY STENT; STENT HAVING AN ULTRASONIC EMITTER; DRUG-ELUTING INTRAVASCULAR PROSTHESES AND METHODS OF USE; IMPLANTABLE DRUG DELIVERY DEVICE AND USE THEREOF; INTRA-AORTIC RENAL DELIVERY CATHETER; SYSTEM AND METHOD FOR DRUG DELIVERY AND MICROFLUIDIC APPLICATIONS USING MICRONEEDLES; ENCAPSULATED INORGANIC ANTIMICROBIAL ADDITIVE FOR CONTROLLED RELEASE; POLYMER NANOTECHNOLOGY
CHAPTER EIGHTEEN: INDUSTRY STRUCTURE AND COMPANY PROFILES: OVERVIEW; REVENUES AND PROFITABILITY; COMPANY PROFILES; ACRYMED, INC.; AFFINERGY, INC.; AGION TECHNOLOGIES, INC.; ALEXZA PHARMACEUTICALS; ALLIED MINDS/BIOTECTIX; ANGIOTECH PHARMACEUTICALS, INC.; ARROW INTERNATIONAL; AVITA MEDICAL; AXCAN PHARMA, INC.; BIND BIOSCIENCES, INC.; BIOCOAT, INC.; BIOCOMPATIBLES UK, LTD.; BIOHEART, INC.; BIOMET, INC.; BRONCUS TECHNOLOGIES, INC.; CELSION CORPORATION; CODMAN & SHURTLEFF, INC.; COLLAGEN MATRIX, INC.; COOK MEDICAL, INC.; CORDIS CORPORATION; COVIDIEN, PLC; CYNOSURE, INC.; DUSA PHARMACEUTICALS, INC.; EDWARDS LIFESCIENCES CORP.; ENDOVASC, INC.; ETEX CORPORATION; EXACTECH, INC.; FORTICELL, INC.; INFRAREDX; INTEGRA LIFESCIENCES HOLDINGS CORP.; INTERPORE CROSS INTERNATIONAL; Interpore Cross International (Continued); ISTA PHARMACEUTICALS; KENSEY NASH CORPORATION; KIADIS PHARMA B.V.; LIFECELL CORP.; MARTECH MEDICAL PRODUCTS; MILLENIUM BIOLOGIX, INC.; MIRAVANT MEDICAL TECHNOLOGIES; MIV THERAPEUTICS INC.; NOVABONE PRODUCTS, LLC; NUCRYST PHARMACEUTICALS, INC.; OMRIX BIOPHARMACEUTICALS, LTD.; ORGANOGENESIS, INC.; ORTHOVITA, INC.; PHARMACYCLICS, INC.; PHOTOCURE ASA; PHOTOBIOTICS; QLT, INC.; SMITH & NEPHEW, PLC; SORIN S.P.A; STRYKER CORP.; SURMODICS, INC.; SYNTHES, INC.; SYSTAGENIX WOUND MANAGEMENT; TEI BIOSCIENCES, INC.; WRIGHT MEDICAL GROUP, INC.; W. L. GORE & ASSOCIATES, INC.; APPENDIX 1: RECENT FDA APPROVALS OF DEVICES, INCLUDING COMBINATION DEVICES; APPENDIX 2: GLOSSARY OF RELEVANT TERMINOLOGY
LIST OF TABLES: SUMMARY TABLE SALES OF DRUG DEVICE COMBINATION; PRODUCTS, THROUGH 2014 ($ BILLIONS); TABLE 1 RECENT EXAMPLES OF FDA APPROVED COMBINATION; PRODUCTS; TABLE 2 FDA CLASSIFICATION SCHEME FOR COMBINATION; PRODUCTS; TABLE 3 FDA COMBINATION PRODUCT CATEGORIES, FY 2004; TABLE 4 FDA COMBINATION PRODUCT CATEGORIES, FY 2005; (NUMBERS AND TYPES OF COMBINATION PRODUCTS); TABLE 5 REVENUES ATTRIBUTABLE TO NANOTECHNOLOGY-BASED; DRUG-DEVICE COMBINATIONS, THROUGH 2014 $ MILLIONS; TABLE 6 MARKETS FOR CORONARY STENTS, THROUGH 2014 $; BILLIONS; TABLE 7 EXAMPLES OF STENTS APPROVED FOR CLINICAL USE; TABLE 8 PHOTODYNAMIC THERAPY MARKETS, THROUGH 2014; ($BILLIONS); TABLE 9 REVENUES ATTRIBUTABLE TO ANTIMICROBIALS; THROUGH 2014 ($ BILLIONS); TABLE 10 REVENUES ATTRIBUTABLE TO MEDICAL DEVICE; COATINGS THROUGH 2014 ($ MILLIONS); TABLE 11 MEDICAL DEVICE PRODUCTS RELYING ON; ANTIMICROBIAL COATINGS; TABLE 12 CATHETER MARKET FORECASTS, BY PRODUCT TYPE,; THROUGH 2014 ($ BILLIONS); TABLE 13 CURRENT CLINICAL TRIALS INVOLVING DRUG-ELUTING; BEADS; TABLE 14 R&D AND REVENUES ATTRIBUTABLE TO DRUG-ELUTED; BEADS, THROUGH 2014 ($ MILLIONS); TABLE 15 CHARACTERISTICS OF IDEAL BONE GRAFT MATERIAL; TABLE 16 BONE GRAFT PROCEDURE VOLUMES BY APPLICATION IN; THE U.S., THROUGH 2014; TABLE 17 BONE GRAFT PROCEDURE VOLUMES BY TYPE OF GRAFT; IN THE U.S., THROUGH 2014; TABLE 18 COMPARISON OF BONE GRAFT MATERIALS; TABLE 19 TYPES OF SUBSTITUTE BONE GRAFTS; TABLE 20 SELECTED DBM PRODUCT AND PERCENTAGE OF; DEMINERALIZED BONE MATRIX; TABLE 21 THE U.S. MARKET FOR PRECISION-MACHINED; ALLOGRAFTS, THROUGH 2014 ($ MILLIONS); TABLE 22 THE WORLDWIDE MARKET FOR BONE REPLACEMENT; PRODUCTS, THROUGH 2014 ($ MILLIONS); TABLE 23 THE U.S. MARKET FOR BONE REPLACEMENT PRODUCTS,; THROUGH 2014 ($ MILLIONS); TABLE 24 IDENTIFICATION OF COLLAGEN-BASED PRODUCTS; TABLE 25 EXAMPLES OF SKIN SUBSTITUTE PRODUCTS; TABLE 26 TOTAL SALES OF ENGINEERED SKIN GRAFTS AND; REPLACEMENTS, THROUGH 2014 ($ MILLIONS); TABLE 27 EXAMPLES OF ALGINATE-BASED PRODUCTS; TABLE 28 EXAMPLE ENZYMATIC DEBRIDING AGENTS; TABLE 29 MARKETS FOR BIOLOGICAL WOUND CARE PRODUCTS; THROUGH 2014 ($ BILLIONS); TABLE 30 MARKETS FOR OCCULAR APPLICATIONS IN DRUG-DEVICE; COMBINATION PRODUCTS, THROUGH 2014 ($ MILLIONS); TABLE 31 IMPLANTABLE DRUG DEVICE COMBINATIONS THROUGH; 2014 ($ MILLIONS); TABLE 32 MARKETS FOR RELATED DRUG-DEVICE COMBINATION; PRODUCTS, THROUGH 2014 ($ MILLIONS); TABLE 33 MEDICAL DEVICES APPROVED BY THE FDA, 2009; TABLE 34 MEDICAL DEVICES APPROVED BY THE FDA, 2008; TABLE 35 MEDICAL DEVICES APPROVED BY THE FDA, 2007
LIST OF FIGURES: SUMMARY FIGURE SALES OF DRUG DEVICE COMBINATION; PRODUCTS, 2008-2014 ($ BILLIONS); FIGURE 1 COMBINATION PRODUCT APPLICATIONS AT FDA, 2003-; 2007 (NUMBER OF SUBMISSIONS)

More Global Drug Delivery Reports

Global Inhaled Antibiotics Market 2011-2015 by Infiniti Research Limited
TechNavio’s analysts forecast the Global Inhaled Antibiotics market to reach US$875 million by 2015. One of the key factors contributing to this market growth is ...

Drug Delivery: Surveying the Global Competitive Landscape by Espicom Healthcare Intelligence
This report provides key insights for you to... Identify exciting development companies with novel drug delivery technologies Find out more about the ...

Nanotechnology for Drug Delivery: Global Market for Nanocarriers by Cientifica Ltd.
Nanocarriers will account for 40% of a $136 billion nanotechnology-enabled drug delivery market by 2021. We forecast the total market size in 2021 ...

Nanotechnology in Medical Applications: The Global Market by BCC Research
INTRODUCTION STUDY GOALS AND OBJECTIVES The aim of this report is to provide detailed market, technology and industry analyses to help readers quantify and qualify ...

Nanotechnology in Drug Delivery: Global Markets by Cientifica Ltd.
Cientifica's latest report, Nanotechnology in Drug Delivery: Global Markets, indicates nanotech-enabled drug delivery therapeutics is set to grow from a current value of $2.3 billion ...

See all reports like this >>

Drug-device Combinations: The Global Market

Share this report

Other tasks

Research Assistance

Related Markets

Drug Delivery Reports

Free Alert Me service